![Show Menu](styles/mobile-menu.png)
![Page Background](./../common/page-substrates/page0084.png)
84
112.
Galiè N, Olschewski H, Oudiz RJ, Torres F,
Frost A, Ghofrani HÁ, et al. Ambrisentan for
the
treatment
of
pulmonary
arterial
hypertension: results of the ambrisentan in
pulmonary arterial hypertension, randomized,
double-blind, placebo-controlled, multicenter,
efficacy (ARIES) study 1 and 2. Circulation
2008;117:3010-9.
113.
Saggar R, Khanna D, Shapiro S, Furst DE,
Maranian P, Clements P, et al. Effect of
ambrisentan treatment on exercise-induced
pulmonary hypertension in systemic sclerosis:
A prospective single-center, open-label pilot
study. Arthritis Rheum 2012;64:4072-7.
114.
Galiè N, Ghofrani HA, Torbicki A, Barst RJ,
Rubin LJ, Badesch D, et al. Sildenafil citrate
therapy for pulmonary arterial hypertension.
N Engl J Med 2005;353:2148-57.
115.
Badesch DB, Hill NS, Burgess G, Rubin LJ,
Barst RJ, Galiè N, et al. Sildenafil for
pulmonary arterial hypertension associated
with connective tissue disease. J Rheumatol
2007;34:2417-22.
116.
Galiè N, Brundage BH, Ghofrani HA, Oudiz
RJ, Simonneau G, Safdar Z, et al. Tadalafil
therapy for pulmonary arterial hypertension.
Circulation 2009;119: 2894-903
117.
DeMarco PJ, Weisman MH, Seibold JR, Furst
DE, Wong WK, Hurwitz EL, et al. Predictors
and outcomes of scleroderma renal crisis: the
high-dose versus low-dose D-penicillamine in